Latest news
Seaport Therapeutics reports Q2 2026 net loss $62.6M, $427.3M cash; advances GlyphAllo and GlyphAgo - TradingViewTradingView · Mon, 03 Aug 2026 11:23:01 GMTSeaport Therapeutics, Inc. 2Q 2026: Revenue $0 Net loss $(62.6)M, EPS $(1.78) — 10-Q Summary - TradingViewTradingView · Mon, 03 Aug 2026 11:21:01 GMTSPTX: Advanced clinical pipeline and strong cash position following $260M IPO, despite higher Q2 losses - TradingViewTradingView · Mon, 03 Aug 2026 11:06:51 GMTSeaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Business WireBusiness Wire · Mon, 03 Aug 2026 11:00:00 GMT